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Objective:Mesenteric artery angioplasty and stenting (MAS) has been plagued by high restenosis and reintervention rates. The
purpose of this study was to review the outcomes of patients treated for mesenteric artery in-stent restenosis (MAISR).
Methods: The clinical data of 157 patients treated for chronic mesenteric ischemia with MAS of 170 vessels was
entered into a prospective database (1998-2010). Fifty-seven patients (36%) developed MAISR after a mean
follow-up of 29 months, defined by duplex ultrasound peak systolic velocity >330 cm/s and angiographic stenosis
>60%. We reviewed the clinical data, radiologic studies, and outcomes of patients who underwent reintervention for
restenosis. End points were mortality and morbidity, patient survival, symptom recurrence, reintervention, and
patency rates.
Results: There were 30 patients (25 female and five male; mean age, 69  14 years) treated with reintervention for
MAISR. Twenty-four patients presented with recurrent symptoms (21 chronic, three acute), and six had asymptomatic
preocclusive lesions. Twenty-six patients (87%) underwent redo endovascular revascularization (rER) with stent
placement in 17 (13 baremetal and four covered) or percutaneous transluminal angioplasty (PTA) in nine. The other four
patients (13%) had open bypass, one for acute ischemia. There was one death (3%) in a patient treated with redo stenting
for acute mesenteric ischemia. Seven patients (27%) treated by rER developed complications, including access site
problems in four patients, and distal embolization with bowel ischemia, congestive heart failure and stent thrombosis in
one each. Symptom improvement was noted in 22 of the 24 symptomatic patients (92%). After a mean follow-up of
29  12 months, 15 patients (50%) developed a second restenosis, and seven (23%) required other reintervention. Rates
of symptom recurrence, restenosis, and reinterventions were 0/4, 0/4, and 0/4 for covered stents, 2/9, 3/9, and 2/9
for PTA, 5/13, 8/13, and 5/13 for bare metal stents, and 1/4, 4/4, and 0/4 for open bypass. For all patients, freedom
from recurrent symptoms, restenosis, and reinterventions were 70%  10%, 60  10%, and 50  10% at 2 years. For
patients treated by rER, secondary patency rates were 72  12 at the same interval.
Conclusions:Nearly 40% of patients developed mesenteric artery in-stent restenosis, of which half required reintervention
because of symptom recurrence or progression to an asymptomatic preocclusive lesion. Mesenteric reinterventions were
associated with low mortality (3%), high complication rate (27%), and excellent symptom improvement (92%). (J Vasc
Surg 2011;54:1422-9.)
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rOver the past decade, mesenteric artery stenting (MAS)
has surpassed open bypass as the most frequently utilized
method of revascularization to treat chronic mesenteric isch-
emia (CMI).1 Several centers have adopted an endovascular-
first approach, relegating open revascularization (OR) to
patients who failed stenting or have anatomy unsuitable for
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1422t.1 In a recent review of national outcomes, Schemerhorn
nd associates1 reported a sevenfold increase in the number
f mesenteric interventions since 1988 and a remarkable
eduction in mortality from 15% with open bypass to 4%
ith endovascular treatment.However, several studies have
emonstrated that mesenteric stents are less durable when
ompared with OR, with higher rates of restenosis in the
ange of 20% to 66%.2-5 Nevertheless, despite these higher
estenoses rates, clinical data on outcomes of mesenteric
einterventions remain scarce.
Treatment is recommended in patients who develop
ymptoms associated with restenoses, but the type of rein-
ervention is individualized considering physician prefer-
nce, patient comorbidities, and anatomical characteristics
f the lesion. Most often, a secondary endovascular proce-
ure is performed using either primary angioplasty or stent
lacement. Alternatively, a mesenteric bypass provides a
urable option and can be performed with low mortality
ates in good-risk patients, particularly in those with fast-
ecurring lesions, occlusions, or unfavorable anatomy. The
im of this study was to review treatment strategies and
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Volume 54, Number 5 Tallarita et al 1423outcomes of patients treated for mesenteric artery in-stent
restenosis (MAISR).
METHODS
The study was approved by the Institutional Review
Board of the Mayo Clinic. The clinical data of patients who
underwent an index MAS procedure for CMI between 1998
and 2010 were entered into a prospectively maintained data-
base. We identified all patients who had follow-up imaging
studies of the treated vessel and were diagnosed and treated
for a MAISR. We excluded from the study patients with
mesenteric artery vasculitis, median arcuate ligament syn-
drome, or those who had hybrid retrograde MAS or reinter-
ventions after failed mesenteric bypass or endarterectomy.
Demographics, clinical characteristics, imaging, and
operative data were obtained from the medical records.
Operative risk was assessed using Society for Vascular Sur-
gery (SVS) clinical scores.6 Patients were classified into a
high- or low-risk category as previously validated by our
group. High-risk was defined by SVS class 3 cardiac, pul-
monary, renal comorbidity or age 80 years old.7 MAISR
was defined by duplex ultrasound (DUS) peak systolic
velocity (PSV) 330 cm/s and/or evidence of in-stent
stenosis 60% by computed tomography angiography
(CTA), magnetic resonance angiography (MRA), or con-
ventional biplane mesenteric angiography.8,9
Mesenteric reinterventions were indicated for recurr-
ent symptoms associated with angiographic evidence of
MAISR. Patients with asymptomatic restenoses were fol-
lowed with repeat DUS. A subset of patients with asymp-
tomatic restenosis was offered a reintervention if the lesion
progressed (PSV  500 cm/s and distal tardus-parvus
waveform) and was associated with poor collateral network
because of occlusion of the other two mesenteric vessels.
The type of reintervention was left at the discretion of the
physician performing the procedure. There was no pre-
defined algorithm, but most often, a second endovascular
intervention included standard balloon angioplasty (percu-
taneous transluminal angioplasty [PTA]), cutting-balloon
angioplasty (cPTA), or placement of bare metal or covered
stent. Mesenteric bypass was indicated in patients who had
acute mesenteric ischemia and needed a laparotomy be-
cause of peritoneal signs, or in patients who had stent
occlusions or long calcified lesions.
The index angiography (first angiography at time of
stent placement) and available pre- and postprocedure im-
aging studies were reviewed by a blinded investigator to
determine anatomical characteristics of the index lesion and
to correlate these findings with the location of the resteno-
sis. CTA with centerline of flow was analyzed for vessel
diameter and length measurements. Target vessel calcifica-
tion was graded as mild (none or trivial), moderate, or
severe (circumferential napkin-ring or 60% eccentric
plaque). Conventional completion angiography was re-
viewed to determine technical success, which was defined
by 30% residual stenosis, and presence of other technical
imperfections, such as partial stent compressions, missed or
tandem lesions. Follow-up consisted of clinical examina- 4ion and DUS prior to dismissal, every 6 months during the
rst year, and annually thereafter. CTA orMRAwas used in
atients who had technically limited DUS or evidence of
ecurrent stenosis. Medical therapy was clopidogrel for 6 to
weeks after an endovascular intervention, followed by
spirin indefinitely; for patients treated by OR, medical
herapy was aspirin indefinitely.
Statistical analysis. Data were analyzed using SVS re-
orting standards. End points were procedure-relatedmortal-
ty and morbidity, and late patient survival, symptom recur-
ence, reintervention, and patency rates. Time-dependent
utcomes were analyzed using Kaplan-Meier estimates, and
ifferences were determined by the log-rank test. The Pearson
2 or Fisher exact test was used for analysis of categoric
ariables. Differences between means were tested with two-
ided t test, the Wilcoxon rank-sum test, or the Mann-
hitney test. A value of P  .05 was used to determine
tatistical significance.
ESULTS
tudy population
One hundred fifty-seven patients (103 female and 54
ale) were treated for CMI with MAS of 170 mesenteric
rteries. From this group, 145 patients (92%) had at least
ne follow-up imaging study of the stented vessel and 57
atients (39%) were diagnosed with MAISR. We included
n the study 30 patients (21%) who underwent reinterven-
ions for MAISR.
linical characteristics
There were 25 female and five male patients with mean
ge of 69 14 years. Patients presented at an average of 12
onths (range, 1-33) after the index procedure, which
ncluded 21 superior mesenteric artery (SMA) and 11 celiac
xis (CA) stents, and three SMA angioplasties. Twenty-four
atients developed recurrent symptoms (Table I), which
ere chronic in 21. Three patients had acute presentation,
ncluding two patients who had chronic abdominal pain
ut did not return for follow-up until they developed acute
ymptoms, and one who had no evidence of in-stent reste-
osis by ultrasound 6 months prior. Cardiovascular risk
actors included hypertension in 24 patients (80%), hyper-
ipidemia in 20 (67%), and coronary artery disease (CAD),
r tobacco use in 19 patients each (63%).
iagnostic imaging and anatomical characteristics
Index angiography. Angiographic studies performed
rior to the first stent placement were analyzed in all
atients, including 26 conventional angiographies, 14
TAs, and six MRAs (Table II, online only). The index
esion was ostial in 17 vessels and nonostial in 15. Five
atients had tandem lesions in the SMA, which were not
reated. The target lesion length measured 16.2 9.4 mm
nd the reference vessel diameter was 6.3 1.6 mm. Seven
esions were severely calcified (27%), eight occurred in small
essels (6 mm), and three were longer than 30 mm (76,
0, and 32 mm).
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November 20111424 Tallarita et alStent length averaged 17.1  6.8 mm. Among 12
patients who had comparative length measurements using
centerline of flow, stents were adequate in length in eight
patients (longer than the lesion) but short in four (33%).
Analysis of the completion angiography showed 30%
residual stenosis in 20 patients (66%) and no residual lesion
in five (17%). Five patients (17%) had 30% residual ste-
nosis. Other technical imperfections were noted in 15
patients (50%), including missed lesion because of short
stent length in 11 (eight proximal and three distal) and
partial stent compression in seven (five SMA and two CA).
Ultrasound surveillance. Sixteen patients had a total
of 64 DUS studies reviewed (Fig 1). The PSV increased
from 307  140 cm/s from the initial study, which was
obtained within the first 3 months, to 440 81 cm/s prior
to the reintervention. After treatment of the restenosis,
PSV averaged 319 151 cm/s, remaining elevated (330
cm/s) in three patients despite a completion angiography
demonstrating no evidence of residual stenosis.
Reintervention angiography. Imaging studies per-
formed prior to the second intervention were analyzed in all
patients, including 30 conventional angiographies and 13
CTAs. Of the 13 CTAs, 11 showed high-grade and two
demonstrated moderate restenosis. Conventional angiog-
Table I. Clinical characteristics of 57 patients who develo
Variables
R
in
n  30
Demographics
Mean age  standard deviation (years)
Female gender 25
Clinical presentation
Abdominal pain 24
Weight loss 16
Nausea and/or vomiting 10
Food fear 10
Cardiovascular risk factors
Hypertension 24
Hyperlipidemia 20
Coronary artery disease 19
Tobacco abuse 19
Peripheral artery disease 15
Prior myocardial infarction 14
Chronic obstructive pulmonary disease 9
Cerebrovascular disease 8
Chronic renal insufficiencya 7
Society for Vascular Surgery comorbidity score
Medical therapy
Acetylsalicylic acid 24
Clopidogrel 23
Statins 17
Beta-blocker 17
ACE inhibitor 14
Diuretic 13
Warfarin 4
aSerum creatinine  1.5 mg/dL.raphy confirmed high-grade restenosis in all patients, in- lluding the six patients with asymptomatic lesion by duplex
S. The location of the restenosis (Fig 2, online only) was
roximal to the stent in 11 patients (10 ostial and one
onostial), within the stent in nine, and distal to the stent in
ix. The five tandem lesions noted at the index angiography
emained stable. Comparative analysis of the index and the
eintervention angiography demonstrated that in 13 pa-
ients (43%) the location of the restenosis coincided with a
echnical imperfection, including 11 missed lesions and
our partial stent compressions. These technical imperfec-
ions were subtle findings and were associated with residual
tenosis 30% in five patients.
Mesenteric reinterventions. Restenoses were treated
y redo endovascular revascularization (rER) in 26 patients
87%) and OR in four (13%). Redo endovascular proce-
ures were performed using a femoral approach in 15
atients or branchial approach in 11. Stents were placed in
7 patients (57%), including 13 patients treated with bare
etal stents and four treated with covered stents (Fig 3,
cast stents; Atrium Medical Corporation, Hudson, NH).
rimary angioplasty was performed using standard balloons
n eight patients (27%) and a cutting balloon in one (3%).
Four patients (13%) underwent open surgical bypass
Fig 4), including three patients who had unfavorable
estenosis
Restenoses
P value
ring
ntion
Not requiring
intervention
% n  27 %
14 78  7 .01
83 18 67 .6
80 0 0 .001
55 0 0 .001
35 0 0 .004
35 0 0 .004
80 25 93 .7
67 21 78 .7
63 21 78 .6
63 15 56 .8
50 14 52 .9
47 13 48 .9
30 13 48 .3
27 8 30 .8
23 4 15 .5
6.0 11.5  4.8
80 13 48 .2
77 8 30 .05
57 11 41 .5
57 13 48 .7
47 15 56 .7
43 5 18 .1
13 1 4 .2ped r
equi
terve
69 
9.5 esions because of long (30mm) calcified stenosis or stent
g
c
a
our t
rmed
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Volume 54, Number 5 Tallarita et al 1425occlusion. The other patient was operated emergently be-
cause of acute mesenteric ischemia and bowel gangrene. A
midline transperitoneal approach was used in all patients.
Fig 1. Duplex ultrasound peak systolic velocity (PSV) m
box) and in the early (green box) and late (blue box) follow
that in a few patients, the PSV remained elevated above
Fig 3. Technique of redo stenting using a covered sten
stenosis (A), the lesion was crossed with a 0.035-inch w
stenosis. The covered stent was positioned under protect
expanded to profile and a completion angiography confiMesenteric reconstruction was performed using an ante- urade supraceliac aortic bypass in three patients (two bifur-
ated celiac and SMA, and one SMA) or a retrograde iliac
rtery to SMA bypass in one patient. A polyester graft was
rements obtained prior to the first reintervention (yellow
after treatment of a mesenteric in-stent restenosis. Note
hreshold of 330 cm/s.
er diagnostic angiography, which depicted the in-stent
ystem and a 7F sheath was advanced across the area of
f the sheath to avoid stent dislodgement. The stent was
no residual stenosis (B).easu
-upt. Aft
ire s
ion osed for all reconstructions, including the patient with
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November 20111426 Tallarita et alacute ischemia who required a Rifampin-soaked graft with
omental wrap.
Early outcomes. There was one procedure-related
death (3%). The patient was an 80-year-old high-risk fe-
male with acute mesenteric ischemia treated by SMA stent
placement, which was complicated by distal embolization.
Despite emergent exploration and bowel resection, the
patient developed multisystem organ failure and died 57
days later. Seven patients (27%) developed complications
after endovascular reinterventions, including four puncture
site complications (two brachial, two femoral) and three
major complications (SVS grade 3). These included the
distal embolization described above, stent thrombosis and
decompensated congestive heart failure, in one patient
each. There were no complications among patients
treated by OR.
Rates of complications were 29% (4/14) for high-risk
and 19% (3/16) for low-risk patients. Endovascular rein-
terventions resulted in decreased length of stay in the
intensive care unit (0.3 1.4 vs 3.7 5.5 days; P .008)
and in the hospital (1.8 2.0 vs 8.2 5.4 days; P .007)
compared with open bypass. Hospital stay was significantly
less (2.3 2.4 vs 6.0 8.7 days; P .001) among patients
who had an elective procedure compared with those who
had reinterventions performed emergently.
Late outcomes. Twenty-nine patients were followed
for an average of 29  12 months (range, 1-101 months).
Symptom improvement was noted in 22 of the 24 symp-
tomatic patients (92%). One patient referred persistent
symptoms despite successful rER. Fifteen patients (50%)
developed a second restenosis and seven (23%) required
additional reinterventions, all indicated for recurrent symp-
toms. Time for the second reintervention averaged 17 19
months. Five patients were treated by SMA angioplasty,
Fig 4. Open reconstruction of a long superior mesenteric artery
(SMA) occlusion (A) using a supraceliac aorta to SMA bypass (B).which was combined with celiac stent in one. Two patients 7nderwent supraceliac aorta to common hepatic and SMA
ypass.
Rates of symptom recurrence, restenosis and reinter-
entions were 0% (0/4), 0% (0/4), and 0% (0/4) for
overed stents, 22% (2/9), 33% (3/9), and 22% (2/9)
or PTA and 38% (5/13), 62% (8/13), and 38% (5/13) for
are metal stents (P  NS). The patient treated by cPTA
eveloped restenosis at 3 months. All four patients treated
y OR had PSV 330 cm/s following revascularization,
ut only one had angiographic confirmation of a significant
estenosis. One patient developed atypical abdominal pain,
ut treatment was not recommended because the symptom
as not consistent with mesenteric ischemia. At 2 years,
reedom from recurrent symptoms, restenosis, and reinter-
entions were 70% 10%, 60 10%, and 50 10% for all
atients (Fig 5). The secondary patency rate of rER was
ig 5. Kaplan-Meier estimates of freedom from symptom re-
urrence (black), reintervention (blue), and restenosis (red) at 2
ears.
ig 6. Kaplan-Meier estimates of secondary patency rates at 2
ears for 26 patients treated with redo endovascular interventions
or mesenteric in-stent restenosis.2%  12% at the same interval (Fig 6).
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Mesenteric artery stenting has surpassed open surgical
bypass as the preferred method of treatment for chronic
mesenteric ischemia in the United States and at most
tertiary care centers. Decisions about the type of revascu-
larization have shifted from patients’ clinical risk (eg, endo-
vascular for high-risk and open bypass for low-risk), to
where the anatomical characteristics of the lesion are
equally or more important. Mesenteric stenting has be-
come the preferred treatment for patients with focal, non-
calcified stenosis, whereas open bypass is considered for
good-risk patients with mesenteric occlusions or long cal-
cified lesions. However, these changes in treatment para-
digm have occurred without a prospective comparison of
both treatment methods. A recent systematic review of the
best available evidence (level IIa, b) indicates that mesen-
teric stenting decreases morbidity and hospital stay, has
similar mortality rate and clinical efficacy, but results in
more restenoses, symptom recurrences, and reinterventions
compared with open bypass.10
The incidence of mesenteric restenosis has varied
widely, from 20% to 66% in prior reports.2-5,11 Possible
explanations for this variability include the lack of reporting
standards, the inconsistent use of imaging studies during
follow-up, and the absence of an ultrasound criterion vali-
dated for in-stent restenosis. Velocity measures used to
diagnose native artery stenosis (200 cm/s for celiac and
275 cm/s for SMA) may overestimate the presence of
restenosis after stent placement. Peck and associates2 found
restenosis in 40% of their patients treated by SMA stenting
using the native artery criterion, while the Oregon group8
found a mean PSV of 336  45 cm/s immediately after
successful stent placement. In a review of ultrasound sur-
veillance studies after SMA stent placement, Stout and
associates9 reported that a PSV 320 cm/s carries a sensi-
tivity of 100% and a specificity of 50% to diagnose an
angiographically proven restenosis 60%. However, this
had a positive predictive value of only 23%, with a negative
predictive value of 100%. Recognizing these limitations, we
have arbitrarily selected a PSV  330 cm/s to diagnose
restenosis by ultrasound and found restenosis in 40% of our
patients, which is similar to the rates reported by Fioole4
(47%) and others.2-4
The ability to predict and identify which patients or
lesions are more prone to restenosis would be helpful and
could optimize treatment selection. Unfortunately, chronic
mesenteric ischemia is relatively uncommon and most re-
ports have a small number of patients or incomplete follow-
up, which does not allow ameaningful analysis of predictive
factors for restenosis. Our prior review of 102 patients
treated by mesenteric stents identified higher rates of reste-
nosis among women, and those treated for occlusions, long
(30 mm) or severely calcified lesions and small vessels
(6 mm).12 Of these factors, occlusions and long lesions
were independently associated with restenosis. In this
study, we identified one of these features in 13 of our
patients (43%) treated for restenosis, including eight pa- bients with vessel diameter 6 mm, seven with severely
alcified lesions, and three with lesions 30 mm. In addi-
ion, we attempted to describe other anatomical predictors
y analyzing the final technical result after the first stent was
laced. Interestingly, 43% of our patients developed reste-
osis in the same location of a technical imperfection, most
ften a missed lesion proximal or distal to the stent edge,
hich was considered minor or subtle at the time of the
nitial procedure. Some of these imperfections may be
revented, such as selection of adequate stent length using
reprocedure cross-sectional imaging, deployment of the
tent within the entire lesion, and flaring the stent in the
ortic origin to avoid residual stenosis. Whereas careful
lanning of these procedures using length measurements
ay improve results, some imperfections may not be im-
roved, such as residual stenosis in patients with densely
alcified lesions.
There are no guidelines on how to treat mesenteric
n-stent restenosis. Most physicians rely on anecdotal expe-
iences and techniques applied for restenoses in other vas-
ular territories. Mesenteric reintervention is indicated for
ecurrent symptoms. In contrast, prophylactic revascular-
zation of an asymptomatic restenosis generally is not ad-
ised, a recommendation that is based on two prospective
ohort studies which demonstrated an exceedingly low risk
f symptom progression in patients with asymptomatic
ingle-vessel disease, therefore not justifying the risks
f revascularization.13,14 However, an older report by
homas and associates14 documented symptom progres-
ion in four of their 15 patients with severe three-vessel
isease. Although we reserve reinterventions for patients
ith recurrent symptoms, we intervened in patients with
symptomatic preocclusive lesions associated with poor
ollateral network between the visceral beds.
A variety of strategies have been used to treat in-stent
estenoses. In the renal territory, a prospective comparison
f angioplasty and stent placement found no differences in
utcome.15 Others have suggested that placement of a
econd stent could be deleterious because of excessive
tretching of the arterial wall, which could further stimulate
evelopment of neointimal hyperplasia.16 Drug-eluting
tents (DES) may prove useful by blocking cellular prolif-
ration and reducing intimal hyperplasia in the treated
essel. The favorable results of DES for native coronary17
nd renal15 artery stenosis encouraged its use to treat
estenosis, but the stent diameters are small (5 mm) for
he mesenteric arteries. While several authors report low
ncidences of recurrent stenosis after treatment of coronary
n-stent restenosis, Stone and associates found no benefit
ith use of DES to treat renal in-stent restenoses when
ompared with bare metal stents.18-20
Cutting balloon angioplasty has been used for resteno-
is of coronary bypasses and applied with success for infrain-
uinal vein graft restenosis. However, its use for in-stent
estenosis is anecdotal. Cutting balloons employ microsur-
ical blades that cut into the lesion, a strategy that reduces
ecoil and may impact formation of neointimal hyperplasia
y inducing a controlled dissection. However, inside a
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cage, which protects the arterial wall. Therefore, its utility
for renal and coronary artery in-stent restenoses is limit-
ed.20-22 We used cutting balloon angioplasty in one pa-
tient, but this resulted in a recurrent lesion.
A promising alternative is the use of covered stents. In
our review of angiographic studies, restenoses affected the
stented segment or the proximal and distal edges of the
stent, indicating that these lesions are consistent with neo-
intimal hyperplasia and typically do not involve jejunal
branches. The use of covered stents may retard the process
of neointimal hyperplasia by acting as a physical barrier.23
Haskal and associates24 reported a prospective randomized
comparison of covered stents and angioplasty alone to treat
restenoses of arteriovenous grafts. Covered stents were
associated with restenosis and patency rates at 6 months of
28% and 51%, vs 78% and 23% for angioplasty alone. Other
authors have reported superior patency rates for covered
stents compared with bare metal stents for renal artery
restenosis or in the setting of fenestrated renal en-
dografts.25,26 Recently, Erdoes and associates27 reviewed
108 patients with chronic mesenteric ischemia treated by
covered or bare metal stents. Primary patency at 1 year was
86% for covered stents and 34% for bare metal stents. In
addition, of the nine patients who had covered stents used
to treat restenosis, only one celiac stent occluded because of
mechanical compression by the median arcuate ligament.
We used covered stents in only four of our patients (Fig 3),
none of whom have developed recurrent stenosis or symp-
toms at an average follow-up of 18months. There are some
limitations of covered stents using the current platform.
These stents are four- to fivefold more expensive than bare
metal stents, have the disadvantages of 0.035-inch system,
need for larger introducer sheath, and carry a risk of stent
dislodgment or inadvertent coverage of side branches. Im-
provements in covered stent technology and growing evi-
dence on its superior patency rates compared with bare
metal stents support the use of covered stents as the primary
stent for native artery stenosis, potentially reducing reinter-
vention rates.
This study has several limitations that deserve com-
ment. We were not able to analyze factors that may have
affected decisionmaking on indications, choice of interven-
tion, or number of vessels treated, because of the retrospec-
tive design and lack of treatment algorithm. We acknowl-
edge that the ultrasound criterion used in this study (PSV
330 cm/s) was arbitrary and has not been validated for
mesenteric stents. The small number of patients treated by
a variety of techniques has limited our ability to compare
outcomes for different methods of treatment. And finally,
our reintervention for silent asymptomatic lesions cannot
be a general recommendation. Nonetheless, the strength
and novelty of the study are the anatomic correlations and
outcomes provided for reinterventions for mesenteric in-
stent restenoses.
In summary, mesenteric artery in-stent restenosis oc-
curred in 40% of our patients treated for chronic mesenteric
ischemia, of which half developed recurrent symptoms andhree presented with acute mesenteric ischemia. This study
hows that reinterventions carry an overall mortality of 3%,
lbeit with no deaths among patients treated electively for
hronic symptoms or progressive asymptomatic lesions.
einterventions effectively relieved symptoms in 92% of the
atients. The ideal endovascular strategy cannot be recom-
ended on the basis of this report, but use of covered stents
ay prove beneficial for most in-stent restenosis. Primary
ngioplasty or bare metal stents may be preferred for lesions
hat extent into side branches. Finally, whereas endovascu-
ar intervention remains our first option to treat mesenteric
n-stent restenosis, open reconstruction should be consid-
red for good-risk patients who develop stent occlusions,
ast recurring lesions or have long calcified lesions.
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November 20111429.e1 Tallarita et alTable II, online only. Anatomical and procedural characteristics of the index procedure in 57 patients who developed
restenosis
Variables
Restenoses
P
Requiring intervention Not requiring intervention
n  30 % n  27 %
Vessel treateda
Superior mesenteric artery 24 75 20 74 .8
Celiac axis 11 25 10 37 .9
Inferior mesenteric artery 0 0 2 7 .2
Lesion characteristicsb
Length (mm) 16.2  9.4 18.5  8.2 .2
Target vessel diameter (mm) 6.3  1.6 7.2  1.8 .2
Ostial 17 53 29 90 .1
Non-ostial 15 47 3 9 .02
Mild calcification 2 7 7 22 .1
Moderate calcification 5 23 5 16 .9
Severe calcification 7 27 8 25 .7
Stent characteristics
Length (mm) 17.1  6.8 18  8.3 .3
Diameter (mm) 5.8  0.8 5.9  1.8 .7
Completion angiography
No residual stenosis 5 17 15 56 .03
Residual stenosis 30% 20 66 6 22 .004
Residual stenosis 30% 5 17 6 22 .7
Technical imperfections 15 50 8 30 .3
Missed lesions 11 37 4 15 .1
Partial stent expansion 7 23 4 15 .7
Tandem lesion 5 17 0 0 .06
aFive and 32 lesions we considered in the two groups.
bOnly 34 CT/CTA were available.Fig 2, online only. Location of restenosis in 30 patients who
underwent interventions for mesenteric in-stent restenoses.
